Anteris Technologies Global (NASDAQ:AVR) Shares Down 4.3% Following Weak Earnings

Key Points

• AVR shares fell 4.3% after second-quarter earnings missed expectations, with a loss of $0.30 per share versus the expected $0.21 loss and revenue of $1.01 million versus the $1.50 million estimate.
• The company remains unprofitable, though its quarterly loss improved from $0.58 per share a year earlier. Analysts still expect a full-year loss of approximately $1.14 per share.
• Anteris secured U.S. Medicare reimbursement eligibility for eligible procedures in its PARADIGM trial, potentially supporting enrollment, but repeated large share sales by major holder L1 Capital may weigh on investor sentiment.

Anteris Technologies Global Corp. (NASDAQ:AVR - Get Free Report)'s share price traded down 4.3% during trading on Wednesday following a dissappointing earnings announcement. The stock traded as low as $8.59 and last traded at $8.7750. 108,992 shares traded hands during trading, a decline of 91% from the average session volume of 1,171,928 shares. The stock had previously closed at $9.17.

The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.09). The company had revenue of $1.01 million during the quarter, compared to analyst estimates of $1.50 million. Anteris Technologies Global had a negative return on equity of 124.76% and a negative net margin of 5,148.78%.During the same quarter last year, the firm posted ($0.58) earnings per share.

Trending Headlines about Anteris Technologies Global

Here are the key news stories impacting Anteris Technologies Global this week:

• Positive Sentiment: Anteris secured U.S. Medicare reimbursement eligibility under a Centers for Medicare & Medicaid Services national coverage policy for eligible procedures in its global pivotal PARADIGM Trial. The policy could improve trial participation and reduce reimbursement-related barriers at U.S. sites. Anteris Technologies Announces Results for the Second Quarter of 2026
• Positive Sentiment: Quarterly EPS improved from a loss of $0.58 in the year-ago period to a loss of $0.30, suggesting year-over-year progress despite the company remaining unprofitable.
• Neutral Sentiment: Analysts continue to project a full-year loss of approximately $1.14 per share, underscoring that AVR remains a development-stage medical-device company whose valuation depends heavily on clinical and regulatory execution.
• Negative Sentiment: Second-quarter results missed expectations: the company reported a $0.30 per-share loss versus the consensus loss estimate of $0.21, while revenue of $1.01 million fell short of the $1.50 million estimate. Anteris also reported an extremely negative net margin and return on equity. Anteris Technologies Announces Results for the Second Quarter of 2026
• Negative Sentiment: Major shareholder L1 Capital Pty Ltd sold 375,815 shares for about $3.50 million on August 11 and 251,844 shares for approximately $2.29 million on August 10. These transactions reduced its position by 7.25% and 4.63%, respectively, following additional recent sales. Repeated large-holder selling may weigh on investor sentiment and increase perceived supply overhang. SEC Filing

Wall Street Analyst Weigh In

Several analysts recently issued reports on AVR shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Anteris Technologies Global in a report on Friday, May 29th. Wall Street Zen upgraded shares of Anteris Technologies Global from a "sell" rating to a "hold" rating in a report on Saturday, May 16th. Finally, Barclays upped their price target on shares of Anteris Technologies Global from $17.00 to $18.00 and gave the company an "overweight" rating in a report on Friday, May 15th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Anteris Technologies Global currently has a consensus rating of "Moderate Buy" and an average price target of $16.00.

Insider Activity at Anteris Technologies Global

In other news, major shareholder L1 Capital Pty Ltd sold 558,633 shares of the stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $8.20, for a total value of $4,580,790.60. Following the completion of the sale, the insider directly owned 6,633,314 shares of the company's stock, valued at approximately $54,393,174.80. This represents a 7.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 3,000,659 shares of company stock worth $25,174,702 in the last three months. 4.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Anteris Technologies Global

Several large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. grew its position in Anteris Technologies Global by 76.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,536 shares of the company's stock worth $29,000 after purchasing an additional 2,841 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Anteris Technologies Global in the first quarter valued at about $32,000. BNP Paribas Financial Markets grew its position in Anteris Technologies Global by 83.3% during the third quarter. BNP Paribas Financial Markets now owns 9,469 shares of the company's stock worth $43,000 after buying an additional 4,302 shares in the last quarter. Bank of America Corp DE grew its position in Anteris Technologies Global by 35.7% during the third quarter. Bank of America Corp DE now owns 10,631 shares of the company's stock worth $48,000 after buying an additional 2,798 shares in the last quarter. Finally, Duncan Williams Asset Management LLC bought a new position in Anteris Technologies Global during the fourth quarter valued at about $54,000.

Anteris Technologies Global Price Performance

The firm has a 50 day moving average of $9.15 and a 200-day moving average of $7.33. The stock has a market capitalization of $853.09 million, a P/E ratio of -3.92 and a beta of 1.78.

Anteris Technologies Global Company Profile

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source